Impax Laboratories, LLC
Impax Laboratories, LLC (IPXL): 12 pipeline candidates · ~9 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.6 months
D/E 19.48 · 0% dilution
Lead: Approved
12 candidates
N/A
N/A
A transparent, data-derived signal for Impax Laboratories, LLCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$104.2M
Quarterly Burn
$85.5M
Runway
8.6 mo
Revenue
$142.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| apixaban | Approved |
| baclofen | Approved |
| bosutinib | Approved |
| bupropion | Approved |
| colesevelam | Approved |
| crexont | Approved |
| crexont er | Phase 4 |
| guanfacine | Approved |
| hydrocortisone | Approved |
| morphine | Approved |
Showing 10 of 12 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Impax Laboratories, LLC's pipeline?
Impax Laboratories, LLC (IPXL) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Impax Laboratories, LLC's lead drug candidate?
Impax Laboratories, LLC's most advanced tracked candidate is apixaban (Approved) for 1 INDICATIONS AND USAGE Apixaban tablets are a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction o.
What is Impax Laboratories, LLC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Impax Laboratories, LLC has approximately 8.6 months of cash runway.
Get the full picture on Impax Laboratories, LLC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.